Kura Oncology (NASDAQ:KURA) Price Target Lowered to $25.00 at Mizuho

Kura Oncology (NASDAQ:KURA) had its target price trimmed by Mizuho from $30.00 to $25.00 in a report published on Tuesday,Benzinga reports. The firm currently has an outperform rating on the stock.

Other analysts also recently issued reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Leerink Partners set a $20.00 target price on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Barclays restated an “overweight” rating and set a $28.00 price target (up from $11.00) on shares of Kura Oncology in a research note on Monday, November 24th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.86.

Kura Oncology Trading Down 3.0%

Shares of Kura Oncology stock opened at $8.07 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06. The company has a market capitalization of $712.82 million, a P/E ratio of -2.54 and a beta of 0.22. Kura Oncology has a 1 year low of $5.41 and a 1 year high of $12.49. The company’s fifty day moving average is $8.47 and its two-hundred day moving average is $9.49.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. The business had revenue of $17.34 million during the quarter, compared to analysts’ expectations of $34.71 million. Analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Activity

In related news, insider Teresa Brophy Bair sold 11,208 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $94,819.68. Following the completion of the sale, the insider owned 226,931 shares in the company, valued at $1,919,836.26. This trade represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian T. Powl sold 6,414 shares of the business’s stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $54,262.44. Following the transaction, the insider owned 183,275 shares in the company, valued at $1,550,506.50. The trade was a 3.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,068 shares of company stock worth $305,135 in the last three months. 6.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Assenagon Asset Management S.A. lifted its stake in shares of Kura Oncology by 37.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company’s stock valued at $11,196,000 after purchasing an additional 345,951 shares during the period. Sector Gamma AS acquired a new position in Kura Oncology during the third quarter worth about $3,880,000. Nan Fung Trinity HK Ltd. purchased a new position in Kura Oncology in the third quarter valued at about $2,043,000. CWM LLC increased its holdings in Kura Oncology by 185.9% in the third quarter. CWM LLC now owns 118,363 shares of the company’s stock valued at $1,048,000 after buying an additional 76,957 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Kura Oncology by 11.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock valued at $11,623,000 after acquiring an additional 211,470 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.